How can virtual pharma companies de-risk new product launches?
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
List view / Grid view
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
Helen Farr, a Partner at Taylor Wessing, discusses the hurdles that life science businesses must tackle to bring employees back to work safely; whether that be working remotely or returning to the lab.
Dr Jonathan Lawson explains why detecting and monitoring exposures and the body’s response from breath could be the key to predicting future health issues.
Kiran Chinnalla and Julian Backhouse explain why automation for labelling in pharma can help the industry to remain compliant in the face of regulatory changes.
Cecilia Avram details the requirements for pharma companies post-Brexit and provides practical pointers on minimising the disruption to cross-border product availability as new rules come into force.
This article explores how implementing Radio Frequency Identification (RFID) technology could help NHS pathology services cope with the challenges of the COVID-19 pandemic.
Barbara Lopez Kunz from the Drug Information Association (DIA) discusses how COVID-19 has impacted clinical trials.
In this article Phoebe Chubb outlines some of the digital solutions that are enabling researchers to continue their work remotely or with social distancing measures, including the Electronic Lab Notebook, Internet of Things (IoT) and automation.
Reeti Banerjee explains why the use of sterile packaging for medicines will see a growth in the near future, mostly due to the COVID-19 pandemic.
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.
Liz Thorn outlines the benefits that in vitro diagnostics can bring to the world in light of the current COVID-19 pandemic.
Relying on manual processes for managing serialised medicines at an individual pack level is a labour intensive and time-consuming process that can disrupt normal operations. In this article, Sébastien Sliski outlines how digitally enabled inventory processes, such as aggregation and consolidation, can help pharmaceutical wholesalers and hospital pharmacies meet their…
The rapid evolution of the COVID-19 situation has created significant barriers to normal operations, from locking down borders to the imposition of restrictions on trade and export – not to mention a surge in demand for many common medicines. Each of these events in isolation can affect production and supply,…
Andrew Dunbar outlines five digital technologies that can help pharma function to the best of its abilities over the course of the COVID-19 pandemic.